Abbott Labs (ABT) Stock: Q1 Earnings Beat Revenue Estimates, Cancer Diagnostics Unit Boosts Results

TLDR

• Abbott reported Q1 EPS of $1.15, matching analyst estimates of $1.14–$1.15
• Revenue came in at $11.16B, beating the $11B consensus estimate
• Cancer diagnostics unit, boosted by the Exact Sciences acquisition, helped drive results
• Medical device unit, Abbott’s largest segment, continued to perform well
• Q2 EPS guidance of $1.25–$1.31 came in slightly below the $1.32 analyst consensus

Abbott Laboratories posted first-quarter results on April 16 that edged past Wall Street’s revenue expectations, with its newly acquired cancer diagnostics business adding a lift.

The company reported adjusted EPS of $1.15 for the quarter. That matched one estimate of $1.15 and came in a penny above another consensus figure of $1.14, depending on the data source.

Total revenue for the quarter hit $11.16 billion, ahead of the $11 billion analysts had expected.

The stock closed at $101.56 heading into earnings. ABT is down 16.59% over the past three months and has lost 22.46% over the past year.

Abbott Laboratories, ABT

The Exact Sciences acquisition played a role in this quarter’s numbers. Abbott agreed to buy the cancer-test maker in November for $105 a share in a deal valued at up to $23 billion. The deal closed in March 2026.

That deal marked one of Abbott’s largest acquisitions and a push into the cancer diagnostics market. Results from that unit contributed to the Q1 beat.

Medical Devices Stay Strong

Abbott’s medical device unit remains its largest by revenue. It continued to deliver in Q1, helping underpin the overall top-line beat.

The company has leaned on its device business as a core revenue driver for several quarters now. That trend held through the first three months of 2026.

Guidance Comes In Just Below Expectations

For Q2 2026, Abbott guided for EPS of $1.25 to $1.31. The analyst consensus sat at $1.32, putting the midpoint of Abbott’s range a touch below Wall Street’s target.

For the full year, Abbott sees EPS of $5.38 to $5.58. The analyst consensus is $5.47, which falls within that range.

Abbott had zero positive EPS revisions and 18 negative EPS revisions in the last 90 days. That’s a shift from the prior quarter’s “great performance” financial health rating — InvestingPro now rates Abbott’s financial health as “good performance.”

The revenue beat offers some reassurance, even if the guidance range didn’t fully satisfy expectations. Abbott’s Q1 top-line performance was the cleaner part of this report.

The full-year EPS consensus of $5.47 sits within Abbott’s guided range of $5.38 to $5.58, which gives some room for the company to meet or beat that figure as the year plays out.

The post Abbott Labs (ABT) Stock: Q1 Earnings Beat Revenue Estimates, Cancer Diagnostics Unit Boosts Results appeared first on CoinCentral.